Gilead disclosed a partial clinical hold affecting two CAR-T cell therapy trials after multiple reported cases of ICANS, a neurological toxicity associated with CAR-T treatment. The company’s move pauses or restricts trial activity while it addresses safety concerns and works with regulators on updated protocols. The disclosure raises renewed scrutiny of risk-management practices for CAR-T therapies, particularly for neurological adverse events, and signals that trial oversight may tighten in response to early signals even when broader safety datasets are still maturing. For sponsors and investigators, the key near-term focus is on what patient populations, dosing schemes, and monitoring procedures remain under study after the hold, and whether trial amendments expand or constrain enrollment timelines.